<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00665717</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 07.05</org_study_id>
    <nct_id>NCT00665717</nct_id>
  </id_info>
  <brief_title>The Influence of Raltegravir on Pravastatin Pharmacokinetics(GRAPPA)</brief_title>
  <acronym>GRAPPA</acronym>
  <official_title>The Influence of Raltegravir on Pravastatin Pharmacokinetics in Healthy Volunteers (GRAPPA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the effect of raltegravir on pravastatin
      pharmacokinetics and vice versa by intrasubject comparison.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pravastatin is a first choice statin for HIV-infected patients. Therefore, raltegravir and
      pravastatin are expected to be co-administered frequently in HIV-infected patients.Since both
      agents share the same metabolic pathway, there is a potential for a pharmacokinetic drug-drug
      interaction.

      Because co-administration will be indicated in many HIV-infected patients, it is essential to
      investigate this potential interaction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of pravastatin and raltegravir.</measure>
    <time_frame>t=0 (predose), 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and (24: for pravastatin only) hours post ingestion on Days 4, 18 and 32. Trough level on Day 2, 16 and 30.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the non-steady state changes in serum low density lipoprotein (LDL) cholesterol secondary to pravastatin use in the presence or absence of raltegravir</measure>
    <time_frame>Screening and Days 1, 5, 15, 19, 29 and 33.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pharmacokinetic parameters</measure>
    <time_frame>at each sampling time</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of combined use of pravastatin and raltegravir</measure>
    <time_frame>entire trial</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pravastatin 40 mg QD for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Raltegravir 400mg BD for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interaction between pravastatin and raltegravir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>40 mg tablet; QD; 4 days</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Selektine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400mg tablet; BD 4 days</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin and raltegravir</intervention_name>
    <description>pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Selektine and Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is at least 18 and not older than 55 years of age.

          -  Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day.

          -  Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2.

          -  Subject is able and willing to sign the Informed Consent Form prior to screening
             evaluations.

          -  Subject is in good age-appropriate health condition.

          -  Subject has a normal blood pressure and pulse rate.

        Exclusion Criteria:

          -  Documented history of sensitivity/idiosyncrasy to medicinal products or exci-pients.

          -  Positive HIV test.

          -  Positive hepatitis B or C test.

          -  Pregnant female or breast-feeding female.

          -  Therapy with any drug.

          -  Relevant history or presence of pulmonary disorders (especially COPD), car-diovascular
             disorders, neurological disorders (especially seizures and mi-graine),
             gastro-intestinal disorders, renal and hepatic disorders, hormonal disorders
             (especially diabetes mellitus), coagulation disorders.

          -  Fasting triglyceride levels &gt; 8.0 mmol/L

          -  Relevant history or current condition that might interfere with drug absorption,
             distribution, metabolism or excretion.

          -  History of or current abuse of drugs, alcohol or solvents.

          -  Inability to understand the nature and extent of the trial and the procedures
             required.

          -  Participation in a drug trial within 60 days prior to the first dose.

          -  Donation of blood within 60 days prior to the first dose.

          -  Febrile illness within 3 days before the first dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Burger, PharmD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/20395869</url>
    <description>Publication in Journal of Acquired Immune Deficiency Syndromes; Issue: Volume 55(1), 1 September 2010, pp 82-86</description>
  </link>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <last_update_submitted>June 6, 2011</last_update_submitted>
  <last_update_submitted_qc>June 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. D.M. Burger, hospital pharmacist</name_title>
    <organization>Radboud University Nijmegen Medical Centre</organization>
  </responsible_party>
  <keyword>interaction</keyword>
  <keyword>statins</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

